29.06.2021 | 6:33 PM
Hypothyroid patients are more likely to be on statins

Context: Treatment with levothyroxine (LT4) that normalizes serum thyrotropin (TSH) is expected to restore lipid metabolism. Objective: To assess statin utilization in LT4-treated patients through an observational drug utilization study. Methods: Three sites were involved: (1) 10 723 outpatients placed on LT4 during 2006-2019 identified from the Clinical Research Data Warehouse of the University of […]

10.09.2020 | 4:35 PM
Human type 1 Iodothyronine deiodinase (DIO1) mutations cause abnormal thyroid hormone metabolism

Background: Iodothyronine deiodinase-1 (D1) selenoenzyme regulates the systemic supply of active thyroid hormone. A transient decrease in D1 enzymatic activity is clinically relevant and adaptive in non-thyroidal illness such as fasting or acute illness. However, DIO1 gene defects have not been reported in humans. Methods: Genetic analysis was performed using whole-exome sequencing in members of two unrelated […]

03.11.2018 | 6:06 PM
Thyroid Hormone Status During L-T4 Therapy: Systematic Review and Meta-Analysis. PMID: 30124904

Importance: The standard of care for overt hypothyroidism is levothyroxine at doses that normalize serum TSH levels. This approach may not universally restore thyroid hormone signaling as patients have increased serum thyroxine-to-triiodothyronine ratios and may report residual symptoms. Objective: To conduct a systematic review of studies of overt, primary hypothyroidism in which participants were treated […]

12.10.2018 | 9:43 PM
Metal Coordinated Liothyronine Tested in Rats for Hypothyroidism. PMID: 30301431

Liothyronine (LT3) has limited short-term clinical applications, all of which aim at suppressing thyrotropin (TSH) secretion. A more controversial application is chronic administration along with levothyroxine in the treatment of hypothyroidism. Long-term treatment with LT3 is complicated by its unique pharmacokinetics that result in a substantial triiodothyronine (T3) peak in the blood three to four hours after oral […]

26.04.2018 | 9:27 PM
Zfp125 Causes Hepatic Steatosis and Hypercholesterolemia. PMID: 29320745

Liver-specific disruption of the type 2 deiodinase gene (Alb-D2KO) results in resistance to both diet-induced obesity and liver steatosis in mice. Here, we report that this is explained by an about 60% reduction in liver zinc-finger protein-125 (Zfp125) expression. Zfp125 is a Foxo1-inducible transcriptional repressor that causes lipid accumulation in the AML12 mouse hepatic cell […]

25.04.2018 | 10:54 AM
A DIO2 Polymorphism And Alzheimer’s Disease Dementia in African And European Americans. PMID: 29481662

CONTEXT: A single nucleotide polymorphism in DIO2, Thr92AlaD2, has been associated with a transcriptome typically found in neurodegenerative diseases in postmortem human brain tissue. OBJECTIVE: To determine whether Thr92AlaD2 is associated with incident Alzheimer’s disease (AD). DESIGN: Population-based study; human brain tissue microarray. SETTING: Community-based cohorts from Chicago, Illinois and northeastern Illinois, as well as […]

20.04.2018 | 2:11 PM
An Online Survey of Hypothyroid Patients Reveals Prominent Dissatisfaction. PMID: 29620972

Approximately 15% more patients taking levothyroxine (LT4) report impaired quality of life compared to controls. This could be explained by additional diagnoses independently affecting the quality of life and complicating assignment of causation. This study sought to investigate the underpinnings of reduced quality of life in hypothyroid patients and to provide data for discussion at […]

23.01.2017 | 4:36 PM
Myocardial inactivation of thyroid hormones in patients with aortic stenosis. PMID: 28095748

Objective: To study myocardial thyroid hormone metabolism in patients with aortic valve stenosis (AS) undergoing aortic valve replacement and in patients with coronary artery disease (CAD) undergoing coronary artery bypass grafting surgery. Context: The human heart expresses the type 2 deiodinase (D2) that activates T4 to T3. At the same time, the inactivating type 3 […]